Cardiff’s stock jumps after sharing promising PhII data for its PLK1 inhibitor onvansertib in pancreatic cancer

Cardiff Oncology saw its stock rise after it announced positive Phase II data from its PLK1 inhibitor onvansertib in second-line metastatic pancreatic ductal adenocarcinoma (mPDAC), spurring plans for an investigator-led trial in first-line treatment.

The San Diego-based company’s stock price $CRDF rose…
Click here to view original post